A rendering of Serán Bioscience's new commercial facility, set to open in 2026 (courtesy Serán)

CD­MO Serán sets out to build first com­mer­cial fa­cil­i­ty, with a $200M in­vest­ment led by Bain Cap­i­tal

Small mol­e­cule con­tract man­u­fac­tur­er Serán Bio­science is build­ing its first com­mer­cial-scale man­u­fac­tur­ing fa­cil­i­ty, backed by a $200 mil­lion in­vest­ment from Bain Cap­i­tal and oth­ers. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA